Diverse endogenous light chains contribute to basement membrane reactivity in nonautoimmune mice transgenic for an anti-laminin Ig heavy chain

2000 ◽  
Vol 51 (1) ◽  
pp. 20-29 ◽  
Author(s):  
M. M. Fitzsimons ◽  
H. Chen ◽  
M. H. Foster
2001 ◽  
Vol 79 (3) ◽  
pp. 222-230 ◽  
Author(s):  
Brenda G Cooperstone ◽  
Mohammed M Rahman ◽  
Earl H Rudolph ◽  
Mary H Foster

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 2774-2774
Author(s):  
Emanuela M. Ghia ◽  
Laura Z. Rassenti ◽  
George F. Widhopf ◽  
Donna S. Neuberg ◽  
Michael J. Keating ◽  
...  

Abstract The use frequency of the immunoglobulin (Ig) heavy chain variable region gene (VH) 3–21 in chronic lymphocytic leukemia (CLL) varies among studies on various cohorts of European patients, ranging from 0.9%–10%. Such variation could be due to geographic/population differences and/or sample-size limitations. We examined a large cohort (N=2,190) of CLL patients evaluated in the United States by the CLL Research Consortium (CRC) and found 56 (2.6%) used IgVH3-21. Thirty-five of the 56 cases (63%) expressed Ig light chains, whereas only 821 (38%) of the 2,134 cases that used IgVH other than IgVH3-21 used light chains, a difference that was highly significant (P < 0.001). Cases that used IgVH3-21 and light chains had significantly fewer amino acid residues in Ig heavy chain third complementarity determining region (CDR3) (m = 11.5 ± 5.3, S.D.) than did VH3-21 cases with light chains (m = 18.4 ± 4.8) (P<0.001). Twenty-eight of the 56 cases (50%) used unmutated IgVH3-21, defined as having >98% homology to germline VH3-21. Twenty (43%) or 18 (38%) of the 47 cases examined by flow cytometry expressed ZAP-70 or high-level CD38, respectively. Although there was frequent concordant expression of ZAP-70 and/or CD38 with unmutated IgVH3-21, such associations were not absolute, as had been noted for CLL cases that did not use IgVH3-21. Thirty-two percent (18/56) of the cases had a previously described common amino-acid motif (ARDANGMDV) in the otherwise highly variable Ig heavy-chain CDR3. Seventeen (94%) of such cases used light chains typically encoded by V3-21/J3. In addition, we identified a novel amino-acid consensus motif (DPSFYSSSWTLFDY) in the Ig heavy chain CDR3 for 3 of the 56 cases (5.4%). We examined the time from diagnosis to initiation of therapy as per established NCI-Working Group guidelines in 40 patients for whom complete clinical data were available. With a median follow-up of 4.2 years from the date of diagnosis, 25 of the 40 patients had received therapy at the time of this analysis. The median time to treatment (TTT) for all 40 patients was 3.5 years, which was significantly shorter than the median TTT of 6.6 years noted for a previously-described CRC cohort of 307 patients that were not selected for use of IgVH3-21 (NEJM2004; 351: 893–901) (P<0.001). The median TTT of 19 patients that used unmutated IgVH3-21 in this subset (3.0 years) appeared shorter than that noted for the 21 patients that had mutated IgVH3-21 (5.4 years), but this difference did not reach statistical significance. We conclude that a small proportion of patients studied in the United States by the CRC use IgVH3-21, which encodes Ig heavy chains that frequently have canonical motifs in the CDR3 and that typically are paired with certain Ig light chains, providing strong evidence for Ig selection by antigen(s). Finally, patients with IgVH3-21-expressing CLL have a higher risk for early disease progression than do patients with CLL not selected for use of IgVH3-21.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 2094-2094
Author(s):  
George F. Widhopf ◽  
Craig J. Goldberg ◽  
Traci L. Toy ◽  
Laura Z. Rassenti ◽  
Thomas J. Kipps

Abstract Analysis of the immunoglobulin (Ig) heavy chains expressed by the leukemic B cells of patients with chronic lymphocytic leukemia (CLL) has demonstrated that expression of Ig variable heavy chain (VH) genes in CLL is not random. Certain VH genes are more frequently expressed in CLL than in the normal adult B cell repertoire, and some, such as the 51p1 allele of VH1-69, also use of certain diversity (D) and junctional (JH) gene segments that encode third complementarity determining regions (CDR3) with conserved molecular structures. We identified 15 CLL cases among 1,220 examined that express nearly identical Ig heavy and light chains, encoded by 51p1/D3-16/JH3 and VKA27, respectively (Blood, 104:2499, 2004). The highly restricted and virtually identical structure of these B cell receptors strongly suggests selection for Ig in CLL that have a particular binding activity. However, little information is currently available about the light chains expressed by CLL B cells that have 51p1-encoded Ig heavy chains that use other D and JH segments encoding CDR3 that also are repeatedly observed in this disease. We analyzed the VL genes used by 235 CLL cases found to express 51p1-encoded Ig heavy chains among 1,605 CLL patients examined. First, we find restricted light chain isotype expression, as 72% of samples express kappa and 28% express lambda light chains, compared to 65% kappa and 35% lambda within the cohort of all 1,605 CRC CLL samples, and about 60% kappa and 40% lambda expression in normal blood B cells. Nucleotide sequence analysis of the Ig light chain V gene used by these 235 cases revealed that each had greater than 98% homology to an identified germline VK or Vl gene. Additionally, we identified non-stochastic pairing of particular VK and Vl genes with 51p1-encoded heavy chains that have highly-conserved CDR3. Twenty of the 235 cases (8.5%) were found to have Ig light chains encoded by VKO2. Seventeen (85%) of such cases had 51p1-encoded Ig heavy chains that used D2-2 and JH6, 15 of which had nearly identical CDR3 using the amino acid motif DIVVVPAAI. The VKO2-encoded light chains paired with these Ig heavy chains all had nearly identical CDR3 with the amino acid sequence motif QQSYSTPRT. Similarly, seven of the 235 cases (3%) were found to have Ig light chains encoded by Vl3-9. Six (86%) of such cases had 51p1-encoded Ig heavy chains that used D3-3 and JH6, and all had highly conserved heavy chain CDR3 with the amino acid motif YDFWSGYYPNYYYYGMDV. The Vl3-9-encoded light chains paired with these Ig heavy chains all had nearly identical CDR3 with the amino acid sequence motif QVWDSSTXV. Finally, we identified seven additional samples that express a heavy chain using D3-16 and JH3 that have nearly identical CDR3 amino acid sequences GGGYDYIWGSYRPNDAFDI, and also express light chains encoded by VKA27. These seven samples combined with the previous 15 represent all of the 51p1-encoded heavy chains that utilize D3-16 and JH3, as well as 52% (22 of 42) of all 51p1-encoded CLL samples that express VKA27-encoded light chains. These studies reveal for the first time that CLL cases using the same unmutated Ig heavy chain have non-stochastic pairing with disparate Ig light chains that is predicated upon the Ig heavy chain CDR3 structure. Because the CDR3 typically forms a major part of antibody binding site(s) for antigen, these data provide compelling evidence for antigen selection of the antibodies expressed in CLL.


1999 ◽  
Vol 35 ◽  
pp. S337
Author(s):  
I. Aurer ◽  
G. Lauc ◽  
D. Rendic ◽  
B. Labar

Blood ◽  
1993 ◽  
Vol 82 (3) ◽  
pp. 853-857 ◽  
Author(s):  
V Buccheri ◽  
B Mihaljevic ◽  
E Matutes ◽  
MJ Dyer ◽  
DY Mason ◽  
...  

The expression of the Ig-linked mb-1 polypeptide was analyzed by immunocytochemistry (alkaline phosphatase anti-alkaline phosphatase technique) using a specific monoclonal antibody in 165 cases of acute leukemia, with 88 being lymphoblastic (ALL) and 77 myeloid (AML). The purpose of the study was to investigate the specificity of this reagent for B-lineage cases and its reactivity on leukemias that coexpress myeloid and B-cell antigens (biphenotypic). The majority (89%) of 72 B- cell precursor ALL patients were positive. Of these, mb-1 was expressed in all 9 patients with early-B-ALL (CD10-, c mu-), in all 11 patients with pre-B-ALL (c mu+) and in the single case of B-ALL (smIgM+). Forty- three of 51 patients with common-ALL (CD10+, c mu+) were also positive. All 16 T-lineage ALL patients and 72 (93.5%) of the AML patients examined were mb-1 negative. Four of the 5 mb-1-positive AML patients were considered biphenotypic and expressed other B-cell antigens such as CD10, CD19, and/or cCD22 and all showed rearrangement of the Ig heavy chain genes. Within the AML cases, mb-1 and cCD22 were more useful than other B-cell antigens in detecting biphenotypic cases, and mb-1 showed the highest correlation with the clonal rearrangement of Ig heavy chain genes. These results indicate that mb-1 is a sensitive and specific reagent for B-lineage blasts that will aid in the classification of B-cell precursor ALL and in the identification of biphenotypic leukemia presenting as AML.


2002 ◽  
Vol 49 (4) ◽  
pp. 789-804 ◽  
Author(s):  
Maria Jolanta Redowicz

This article summarizes current knowledge on the genetics and possible molecular mechanisms of Human pathologies resulted from mutations within the genes encoding several myosin isoforms. Mutations within the genes encoding some myosin isoforms have been found to be responsible for blindness (myosins III and VIIA), deafness (myosins I, IIA, IIIA, VI, VIIA and XV) and familial hypertrophic cardiomyopathy (beta cardiac myosin heavy chain and both the regulatory and essential light chains). Myosin III localizes predominantly to photoreceptor cells and is proved to be engaged in the vision process in Drosophila. In the inner ear, myosin I is postulated to play a role as an adaptive motor in the tip links of stereocilia of hair cells, myosin IIA seems to be responsible for stabilizing the contacts between adjacent inner ear hair cells, myosin VI plays a role as an intracellular motor transporting membrane structures within the hair cells while myosin VIIA most probably participates in forming links between neighbouring stereocilia and myosin XV probably stabilizes the stereocilia structure. About 30% of patients with familial hypertrophic cardiomyopathy have mutations within the genes encoding the beta cardiac myosin heavy chain and both light chains that are grouped within the regions of myosin head crucial for its functions. The alterations lead to the destabilization of sarcomeres and to a decrease of the myosin ATPase activity and its ability to move actin filaments.


2001 ◽  
Vol 22 (7) ◽  
pp. 400-405 ◽  
Author(s):  
Kimberly D. Klonowski ◽  
Marc Monestier

Sign in / Sign up

Export Citation Format

Share Document